A Study of Olverembatinib in SDH-deficient GIST.
Study sponsor: Ascentage Pharma Group Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-03-31Estimated
Enrollment · participants40Estimated
Source updated2026-07-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.